Novel taxanes in development: Hopes or hypes?

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Taxanes are crucial cytotoxic agents in solid tumor treatment.
• Taxane-induced peripheral neuropathy (PN) and drug resistance are significant clinical challenges.

Purpose of the Study:

• To review the evolution of taxane development in breast cancer.
• To highlight novel taxanes, including oral formulations, and their potential to overcome resistance and reduce PN.
• To discuss ongoing research and future directions in taxane-based cancer therapy.

Main Methods:

• Literature review of taxane history, current applications, and future prospects.
• Analysis of novel taxane classifications (semisynthetic, analogs, new delivery methods, oral, P-gp resistant, BBB-penetrant).
• Discussion of clinical trial outcomes, including mature phase III trials of oral taxanes.

Main Results:

• Novel taxanes demonstrate promising clinical activity and the potential to overcome traditional taxane resistance.
• Oral taxanes represent a significant advancement, though clinical trial outcomes have shown both promise and setbacks.
• Exploration of predictive biomarkers aims to enable precision medicine approaches for taxane therapy.

Conclusions:

• Taxane development continues to evolve, offering new therapeutic options for breast cancer.
• Novel taxanes, particularly oral formulations, hold potential for improved patient outcomes.
• Future research should focus on optimizing taxane efficacy, managing resistance, and personalizing treatment through biomarkers.